TY - JOUR
T1 - Antiplatelet therapy in acute coronary syndromes
AU - Barker, Colin M.
AU - Price, Matthew J.
PY - 2008
Y1 - 2008
N2 - Acute coronary syndromes (ACS), characterized by unstable angina or a non-ST-segment elevation myocardial infarction, are caused by rupture of an atherosclerotic plaque, leading to platelet activation and aggregation, thrombus formation, and microembolization. Antiplatelet therapy is a cornerstone of therapy. Combined with aspirin, clopidogrel provides significant benefit for patients across the ACS spectrum. However, clopidogrel has limitations given its slow onset and the inconsistent level of inhibition that it achieves. Newer thienopyridine and non-thienopyridine P2Y12 receptor agonists offer the advantages of a rapid onset of action and greater and more consistent platelet inhibition.
AB - Acute coronary syndromes (ACS), characterized by unstable angina or a non-ST-segment elevation myocardial infarction, are caused by rupture of an atherosclerotic plaque, leading to platelet activation and aggregation, thrombus formation, and microembolization. Antiplatelet therapy is a cornerstone of therapy. Combined with aspirin, clopidogrel provides significant benefit for patients across the ACS spectrum. However, clopidogrel has limitations given its slow onset and the inconsistent level of inhibition that it achieves. Newer thienopyridine and non-thienopyridine P2Y12 receptor agonists offer the advantages of a rapid onset of action and greater and more consistent platelet inhibition.
UR - http://www.scopus.com/inward/record.url?scp=54449095851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54449095851&partnerID=8YFLogxK
U2 - 10.1007/s11886-008-0052-y
DO - 10.1007/s11886-008-0052-y
M3 - Review article
C2 - 18611368
AN - SCOPUS:54449095851
VL - 10
SP - 327
EP - 333
JO - Current Cardiology Reports
JF - Current Cardiology Reports
SN - 1523-3782
IS - 4
ER -